LEADER 01041nam0-2200301 --450 001 9910377360303321 005 20200310090522.0 010 $a978-88-255-2392-8 100 $a20200310d2019----kmuy0itay5050 ba 101 0 $aita 102 $aIT 105 $a 001yy 200 1 $aEcologia è buongoverno$ela questione ambientale in Italia attraverso la visione, l?iniziativa riformista e le polemiche di un ecologista scomodo$fMario Signorino$ga cura di Rosa Filippini 210 $aCanterano$cAracne$d©2019 215 $a251 p.$cill.$d21 cm 225 1 $aA14 610 0 $aSviluppo sostenibile$aPolitica$aItalia$a1960-2015$aRaccolte di saggi 610 0 $aAssociazioni ecologiste$aItalia$a1960-2015 676 $a320.58$v23$zita 700 1$aSignorino,$bMario$f<1938-2016>$0782007 702 1$aFilippini,$bRosa 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a9910377360303321 952 $aVII C 546$b1017/2020$fFSPBC 959 $aFSPBC 996 $aEcologia è buongoverno$91734277 997 $aUNINA LEADER 04672oam 22006854a 450 001 9910466810103321 005 20210915044106.0 010 $a1-5017-1391-4 024 7 $a10.1515/9781501713910 035 $a(CKB)3840000000334826 035 $a(MiAaPQ)EBC4982975 035 $a(OCoLC)1017610502 035 $a(MdBmJHUP)muse65579 035 $a(DLC) 2017022718 035 $a(StDuBDS)EDZ0001929381 035 $a(DE-B1597)496601 035 $a(OCoLC)986788847 035 $a(DE-B1597)9781501713910 035 $a(Au-PeEL)EBL4982975 035 $a(CaPaEBR)ebr11501959 035 $a(EXLCZ)993840000000334826 100 $a20170426d2017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aPrescription for the People$eAn Activist?s Guide to Making Medicine Affordable for All /$fFran Quigley 210 1$aIthaca :$cILR Press, an imprint of Cornell University Press,$d2017. 210 4$d©2017. 215 $a1 online resource (260 pages) 225 0 $aThe culture and politics of health care work 300 $aPreviously issued in print: 2017. 311 $a1-5017-1392-2 311 $a1-5017-1375-2 320 $aIncludes bibliographical references and index. 327 $aPeople everywhere are struggling to get the medicines they need -- The United States has a drug problem -- Millions of people are dying needlessly -- Cancer patients face particularly deadly barriers to medicines -- The current medicine system neglects many major diseases -- Corporate research and development investments are exaggerated -- The current system wastes billions on drug marketing -- The current system compromises physician integrity and leads to unethical corporate behavior -- Medicines are priced at whatever the market will bear -- Pharmaceutical corporations reap history-making profits -- The for-profit medicine arguments are patently false -- Medicine patents are extended too far and too wide -- Patent protectionism stunts the development of new medicines -- Governments, not private corporations, drive medicine innovation -- Taxpayers and patients pay twice for patented medicines -- Medicines are a public good -- Medicine patents are artificial, recent, and government-created -- The United States and big pharma play the bully in extending patents -- Pharma-pushed trade agreements steal the power of democratically elected governments -- Current law provides opportunities for affordable generic medicines -- There is a better way to develop medicines -- Human rights law demands access to essential medicines. 330 $aIn Prescription for the People, Fran Quigley diagnoses our inability to get medicines to the people who need them and then prescribes the cure. He delivers a clear and convincing argument for a complete shift in the global and U.S. approach to developing and providing essential medicines-and a primer on how to make that change happen. Globally, 10 million people die each year because they are unable to pay for medicines that would save them. The cost of prescription drugs is bankrupting families and putting a strain on state and federal budgets. Patients' desperate need for affordable medicines clashes with the core business model of the powerful pharmaceutical industry, which maximizes profits whenever possible. It doesn't have to be this way. Patients and activists are aiming to make all essential medicines affordable by reclaiming medicines as a public good and a human right, instead of a profit-making commodity. In this book, Quigley demystifies statistics and terminology, offers solutions to the problems that block universal access to medicines, and provides a road map for activists wanting to make those solutions a reality. 410 0$aCulture and politics of health care work. 606 $aHealth care reform$zUnited States 606 $aPharmaceutical industry$zUnited States 606 $aPharmaceutical policy$zUnited States 606 $aDrug accessibility$zUnited States 606 $aPrescription pricing$zUnited States 606 $aDrugs$xPrices$zUnited States 608 $aElectronic books. 615 0$aHealth care reform 615 0$aPharmaceutical industry 615 0$aPharmaceutical policy 615 0$aDrug accessibility 615 0$aPrescription pricing 615 0$aDrugs$xPrices 676 $a338.4/36150973 700 $aQuigley$b Fran$f1962-$0965406 801 0$bMdBmJHUP 801 1$bMdBmJHUP 906 $aBOOK 912 $a9910466810103321 996 $aPrescription for the People$92428285 997 $aUNINA LEADER 05018oam 2200721zu 450 001 9910142452003321 005 20220610194751.0 010 $a9786610555512 010 $a0-470-84666-6 010 $a1-280-55551-3 035 $a(CKB)111056485557296 035 $a(SSID)ssj0000119155 035 $a(PQKBManifestationID)11140933 035 $a(PQKBTitleCode)TC0000119155 035 $a(PQKBWorkID)10056819 035 $a(PQKB)10103156 035 $a(MiAaPQ)EBC4956314 035 $a(Au-PeEL)EBL4956314 035 $a(CaONFJC)MIL55551 035 $a(OCoLC)1027155361 035 $a(EXLCZ)99111056485557296 100 $a20160829d2001 uy 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe cell cycle and development: Novartis Foundation symposium 237, volume 237 205 $a1st ed. 210 31$a[Place of publication not identified]$cWiley$d2001 215 $a1 online resource (268 pages) 225 1 $aNovartis Foundation Symposia ;$vv.293 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-471-49662-6 311 $a0-470-85184-8 327 $aMachine generated contents note: Paul Nurse Introduction 1 -- Bruce A. Edgar, Jessica Britton, Aida Flor A. de la Cruz, Laura A. Johnston, -- Dara Lehman, Cristina Martin-Castellanos and David Prober -- Pattern- and growth-linked cell cycles in Drosophila development 3 -- Discussion 12 Wolf Reik, Karen Davies,Wendy Dean, Gavin Kelsey and Miguel Constancia -- Imprinted genes and the coordination of fetal and postnatal growth in -- mammals 19 Discussion 31 General discussion I 36 Christian F. Lehner, Henning W. Jacobs, K. Sauer and Claas A. Meyer -- Regulation of the embryonic cell proliferation by Drosophila cyclin D and cyclin E -- complexes 43 Discussion 54 James L. Maller, Stefan D. Gross, Markus S. Schwab, CarlaV. Finkielstein, -- Frederic E. Taieb and Yue-Wei Qian Cell cycle transitions in early Xenopus -- development 58 Discussion 73 Jacek Z. Kubiak and Maria A. Ciemerych Cell cycle regulation in early mouse -- embryos 79 Discussion 89 General discussion II Regulation of Drosophila imaginal disc growth by the -- insulin/IGF signalling pathway 93 -- Martin Raff, Jim Apperly,Toru Kondo,YasuhitoTokumoto and -- Dean Tang Timing cell-cycle exit and differentiation in oligodendrocyte -- development 100 Discussion 107 Kim Nasmyth, Jan-Michael Peters and Frank Uhlmann Splitting the -- chromosome: cutting the ties that bind sister chromatids 113 Discussion 133 William Chia,Yu Cai, Xavier Morin, Murni Tio, Gerald Udolph, Fengwei Yu -- and Xiaohang Yang The cell cycle machinery and asymmetric cell division of -- neural progenitors in the Drosophila embryonic central nervous system 139 Discussion 151 General discussion III Determining organ size 158 -- Pierre Gdnczy, Stephan Grill, Ernst H. K. Stelzer, Matthew Kirkham and -- Anthony A. Hyman Spindle positioning during the asymmetric first cell -- division of Caenorhabditiselegans embryos 164 Discussion 176 PeterJ. Bryant Growth factors controlling imaginal disc growth in Drosophila 182 Discussion 194 General discussion IV Spatial organization and the cell cycle 200 -- Victor Ambros The temporal control of cell cycle and cell fate in Caenorhabditis -- elegans 203 Discussion 214 Jessica Greenwood,Vincenzo Costanzo, Kirsten Robertson, Carmel Hensey and -- Jean Gautier Responses to DNA damage in Xenopus: cell death or cell cycle -- arrest 221 Discussion 230 Martin Hobe, Ulrike Brand, Richard Waites and Rildiger Simon Control of cell -- fate in plant meristems 235 Discussion 243 Final discussion 248 -- Index of contributors 252 -- Subject index 254. 330 $aThis book brings together scientists working at the interface between the cell cycle, cell growth and development in a variety of model systems and research paradigms. The focus is on understanding how such diverse developmental inputs can modulate cell cycle regulation and, reciprocally, how a common way of regulating cell cycle progression can participate in different developmental strategies. 410 0$aNovartis Foundation Symposia 606 $aCell Cycle 606 $aCell Differentiation 606 $aCell Division 606 $aDevelopmental Biology 606 $aBiology$2HILCC 606 $aHealth & Biological Sciences$2HILCC 606 $aCytology$2HILCC 608 $aCongress. 615 12$aCell Cycle. 615 22$aCell Differentiation. 615 22$aCell Division. 615 22$aDevelopmental Biology. 615 7$aBiology 615 7$aHealth & Biological Sciences 615 7$aCytology 676 $a571.84 702 $aCardew$b Gail 702 $aGoode$b Jamie 702 $aBock$b Gregory 712 02$aNovartis Foundation. 801 0$bPQKB 906 $aBOOK 912 $a9910142452003321 996 $aThe cell cycle and development: Novartis Foundation Symposium 237, Volume 237$92013714 997 $aUNINA LEADER 02935nam 2200589Ia 450 001 9910782336203321 005 20230607222222.0 010 $a1-281-80315-4 010 $a9786611803155 010 $a0-567-39136-1 035 $a(CKB)1000000000551611 035 $a(EBL)436519 035 $a(OCoLC)285464564 035 $a(SSID)ssj0000144677 035 $a(PQKBManifestationID)11911969 035 $a(PQKBTitleCode)TC0000144677 035 $a(PQKBWorkID)10145673 035 $a(PQKB)10023217 035 $a(MiAaPQ)EBC436519 035 $a(Au-PeEL)EBL436519 035 $a(CaPaEBR)ebr10256265 035 $a(CaONFJC)MIL180315 035 $a(OCoLC)893334080 035 $a(EXLCZ)991000000000551611 100 $a20021128d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aEgypt on the Pentateuch's ideological map$b[electronic resource] $econstructing biblical Israel's identity /$fF.V. Greifenhagen 210 $aLondon ;$aNew York $cSheffield Academic Press$dc2002 215 $a1 online resource (345 p.) 225 0 $aJournal for the study of the Old Testament. Supplement series ;$v361 300 $aDescription based upon print version of record. 311 $a0-8264-6211-1 320 $aIncludes bibliographical references (p. [277]-306) and indexes. 327 $aContents; Acknowledgments; Abbreviations; Chapter 1 INTRODUCTION; Chapter 2 EGYPT IN GENESIS; Chapter 3 EGYPT IN EXODUS; Chapter 4 EGYPT IN LEVITICUS, NUMBERS AND DEUTERONOMY; Chapter 5 THE PRODUCTION AND PROMULGATION OF THE 'FINAL TEXT FORM' OF THE PENTATEUCH; Chapter 6 THE HISTORICAL CONTEXT: EGYPT AND ISRAEL; Chapter 7 SUMMARY AND CONCLUSIONS; Appendix: THE TERM [Omitted] AND ITS OCCURRENCES IN THE HEBREW BIBLE AND THE PENTATEUCH; Bibliography; Index of References; Index of Authors 330 $aThis book explores the references to Egypt in the Pentateuch--twice as dense as in the rest of the Hebrew Bible--in the context of the production of the text's final form during the Persian period. Here, as Greifenhagen shows, Egypt functions ideologically as the primary ""other"" over against which Israel's identity is constructed, while its role in Israel's formation appears as subsidiary and as a superseded stage in a master narrative which locates Israel's ethnic roots in Mesopotamia. But the presentation of this powerful neighbour is equivocal: a dominant anti-Egyptian stance coexists wit 410 4$aThe Library of Hebrew Bible/Old Testament Studies 606 $aEgypt in the Bible 607 $aEgypt$xIn the Bible 615 0$aEgypt in the Bible. 676 $a222.106 700 $aGreifenhagen$b F. V$01548658 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910782336203321 996 $aEgypt on the Pentateuch's ideological map$93805837 997 $aUNINA